Q1 EPS Estimate for Sarepta Therapeutics Lowered by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Equities research analysts at Zacks Research dropped their Q1 2025 earnings estimates for shares of Sarepta Therapeutics in a report issued on Monday, May 5th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings of ($2.70) per share for the quarter, down from their previous estimate of $1.56. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.67 per share. Zacks Research also issued estimates for Sarepta Therapeutics' FY2025 earnings at $3.55 EPS.

A number of other research analysts have also issued reports on SRPT. Scotiabank reduced their price objective on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Wells Fargo & Company assumed coverage on shares of Sarepta Therapeutics in a report on Friday, April 11th. They issued an "overweight" rating and a $115.00 price objective on the stock. Needham & Company LLC reduced their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a research note on Thursday, April 3rd. Finally, Piper Sandler decreased their target price on shares of Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Six investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $157.95.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $46.75 on Wednesday. The stock has a market capitalization of $4.59 billion, a P/E ratio of 37.40 and a beta of 0.85. The firm's 50-day moving average price is $70.87 and its two-hundred day moving average price is $102.57. Sarepta Therapeutics has a 52-week low of $36.79 and a 52-week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insiders Place Their Bets

In related news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.70% of the company's stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Louisiana State Employees Retirement System grew its position in Sarepta Therapeutics by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock valued at $3,222,000 after purchasing an additional 100 shares in the last quarter. EP Wealth Advisors LLC grew its holdings in shares of Sarepta Therapeutics by 2.2% during the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock valued at $606,000 after acquiring an additional 105 shares in the last quarter. Manchester Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 110 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Sarepta Therapeutics by 36.0% in the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock worth $63,000 after acquiring an additional 138 shares during the last quarter. Finally, CIBC Asset Management Inc raised its holdings in shares of Sarepta Therapeutics by 5.1% during the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after acquiring an additional 139 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.